ATTAIN Trial Drug
The ATTAIN trial studied orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment 1.
Trial Details
The ATTAIN-1 trial (NCT05869903) was a phase 3, multinational, randomized, double-blind study that examined once-daily orforglipron at doses of 6 mg, 12 mg, or 36 mg compared with placebo over 72 weeks in 3,127 adults with obesity without diabetes 1.
Key Efficacy Results
Orforglipron demonstrated dose-dependent weight loss significantly superior to placebo:
- 36 mg dose: -11.2% mean weight reduction (vs -2.1% placebo; P<0.001)
- 12 mg dose: -8.4% mean weight reduction
- 6 mg dose: -7.5% mean weight reduction
At the highest dose (36 mg), 54.6% of patients achieved ≥10% weight loss, 36.0% achieved ≥15% weight loss, and 18.4% achieved ≥20% weight loss 1.
Cardiometabolic Benefits
Beyond weight loss, orforglipron treatment significantly improved:
- Waist circumference
- Systolic blood pressure
- Triglyceride levels
- Non-HDL cholesterol levels 1
Safety Profile
The adverse event profile was consistent with other GLP-1 receptor agonists, with predominantly mild-to-moderate gastrointestinal effects being most common. Treatment discontinuation due to adverse events occurred in 5.3-10.3% of orforglipron-treated patients versus 2.7% with placebo 1.
Note: This is distinct from the ATTAIN trials in infectious disease, which studied telavancin (a lipoglycopeptide antibiotic) for hospital-acquired pneumonia 2.